Journal Watch · European Journal of Immunology · 2026
CD39 on CD8<sup>+</sup> Tumour-Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression.
This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour-reactive cells that express it.
TL;DR
This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour-reactive cells that express it.
Key findings
- CD39<sup>+</sup>CD8<sup>+</sup> TILs thus represent simultaneously the best cellular evidence that a productive anti-tumour immune response has occurred, and among the most potent local drivers of its suppression.
- This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour-reactive cells that express it.
What they did
Yet the same enzymatic activity that defines CD39, the hydrolysis of extracellular ATP (eATP) to AMP, directly feeds CD73-dependent adenosine generation. These very cells therefore actively perpetuate the immunosuppressive purinergic milieu that constrains their own effector function and that of surrounding immune cells.
Full abstract (original)
Background: CD39 (ENTPD1) occupies a paradoxical position in the immunology of solid tumours. On CD8<sup>+</sup> tumour-infiltrating lymphocytes (TILs), its surface expression serves as one of the most reliable available markers of genuine tumour-antigen experience and identifies the clonally expanded tissue-resident and cytolytically competent T cells, that are largely absent from the bystander populations, which are specific for tumour-unrelated antigens and numerically dominate many tumour infiltrates.
What they did: Yet the same enzymatic activity that defines CD39, the hydrolysis of extracellular ATP (eATP) to AMP, directly feeds CD73-dependent adenosine generation. These very cells therefore actively perpetuate the immunosuppressive purinergic milieu that constrains their own effector function and that of surrounding immune cells.
Results & conclusions: CD39<sup>+</sup>CD8<sup>+</sup> TILs thus represent simultaneously the best cellular evidence that a productive anti-tumour immune response has occurred, and among the most potent local drivers of its suppression. This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour-reactive cells that express it.
Abstract © the authors / European Journal of Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/eji.70288 · PubMed 42847334.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking European Journal of Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this European Journal of Immunology study find?
This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour-reactive cells that express it.
What type of study is this?
It is a review / perspective, published in European Journal of Immunology in 2026. Yet the same enzymatic activity that defines CD39, the hydrolysis of extracellular ATP (eATP) to AMP, directly feeds CD73-dependent adenosine generation.
Where can I read the original paper?
The original is at the publisher via DOI 10.1002/eji.70288. PubMed ID: 42847334. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/cd39-on-cd8-lt-sup-gt-lt-sup-gt-tumour-infiltrating-lymphocytes-a-parado-i70288/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides